11 juli 2012: Onderaan artikel resultaten plus referentielijst van deze studie toegevoegd: Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel die aantoont dat chemo bij eierstokkanker weinig zinvol is.
25 februari 2005: Bron: J Clin Oncol. 2004 Jul 1;22(13):2635-42.
Topotecan na operatie toegediend bij eierstokkankerpatiënten stadium III en IV en onderzocht in gerandomiseerde fase III studie - 273 eierstokkankerpatiënten namen deel - tegenover carboplatin/paclitaxel geeft geen enkele meerwaarde. De tijd tot recidief was zelfs korter in de topotecangroep dan in de carboplatin/paclitacelgroep. Hier het abstract van deze studie.
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Carteni G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S. Istituto Nazionale Tumori, via M Semmola, 80131-Napoli, Italy; e-mail: sandro.pignata@fondazionepascale.it
PURPOSE: Topotecan is an active second-line treatment for advanced ovarian cancer. Its efficacy as consolidation treatment after first-line standard chemotherapy is unknown.
PATIENTS AND METHODS: To investigate whether topotecan (1.5 mg/m(2) on days 1 through 5, four cycles, every 3 weeks) prolonged progression-free survival (PFS) for patients responding to standard carboplatin (area under the curve 5) and paclitaxel (175 mg/m(2) administered as a 3-hour infusion in six cycles; CP), a multicenter phase III study was performed with an 80% power to detect a 50% prolongation of median PFS. Patients were registered at diagnosis and randomized after the end of CP.
RESULTS: Two hundred seventy-three patients were randomly assigned (topotecan, n = 137; observation, n = 136), with a median age of 56 years. Stage at diagnosis was advanced in three fourths of patients (stage III in 65% of patients; stage IV in 10%); after primary surgery, 46% had no residual disease and 20% were optimally debulked. After CP, 87% reached a clinical complete response, and 13% achieved a partial response. Neutropenia (grade 3/4 in 58% of the patients) and thrombocytopenia (grade 3 in 21%; grade 4 in 3%) were the most frequent toxicities attributed to topotecan. There was no statistically significant difference in PFS between the arms (P =.83; log-rank test): median PFS was 18.2 months in the topotecan arm and 28.4 in the control arm. Hazard ratio of progression for patients receiving topotecan was 1.18 (95% CI, 0.86 to 1.63) after adjustment for residual disease, interval debulking surgery, and response to CP.
CONCLUSION: The present analysis indicates that consolidation with topotecan does not improve PFS for patients with advanced ovarian cancer who respond to initial chemotherapy with carboplatin and paclitaxel.
PMID: 15226331 [PubMed - indexed for MEDLINE]
Topotecan and cisplatin, followed by carboplatin and paclitaxel, were more toxic than carboplatin and paclitaxel alone, but without improved efficacy
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Source
BC Cancer Agency, Vancouver Clinic, 600 West 10 Ave, Vancouver, BC, Canada V5Z 4E6. phoskins@bccancer.bc.ca
Abstract
BACKGROUND:
Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a novel combination compared with standard frontline therapy.
METHODS:
Women aged 75 years or younger with newly diagnosed stage IIB or greater ovarian cancer, Eastern Cooperative Oncology Group Performance Status of 1 or less, were stratified by type of primary surgery and residual disease, treatment center, and age; then randomly assigned to one of the two 21-day intravenous regimens. Patients in arm 1 (n = 409) were administered four cycles of cisplatin 50 mg/m(2) on day 1 and topotecan 0.75 mg/m(2) on days 1-5, then four cycles of paclitaxel 175 mg/m(2) over 3 hours on day 1 followed by carboplatin (area under the curve = 5) on day 1. Patients in arm 2 (n = 410) were given paclitaxel plus carboplatin as in arm 1 for eight cycles. We compared progression-free survival (PFS), overall survival, and cancer antigen-125 normalization rates in the two treatment arms. A stratified log-rank test was used to assess the primary endpoint, PFS. All statistical tests were two-sided.
RESULTS:
A total of 819 patients were randomly assigned. At baseline, the median age of the patients was 57 years (range = 28-78); 81% had received debulking surgery, and of these, 55% had less than 1 cm residual disease; 66% of patients were stage III and 388 (47.4%) patients had measurable disease. After a median follow-up of 43 months, 650 patients had disease progression or died without documented progression and 406 had died. Patients in arm 1 had more hematological toxicity and hospitalizations than patients in arm 2; PFS was 14.6 months in arm 1 vs 16.2 months in arm 2 (hazard ratio = 1.10, 95% confidence interval = 0.94 to 1.28, P = .25). Among patients with elevated baseline cancer antigen-125, fewer in arm 1 than in arm 2 had levels return to normal by 3 months after random assignment (51.6% vs 63.3%, P = .007)
CONCLUSIONS:
Topotecan and cisplatin, followed by carboplatin and paclitaxel, were more toxic than carboplatin and paclitaxel alone, but without improved efficacy. Carboplatin plus paclitaxel remains the standard of care for advanced epithelial ovarian cancer.
Comment in
- Another confirmation of the inactivity of topotecan in ovarian cancer. [J Natl Cancer Inst. 2010]
- PMID:
- 20937992
- [PubMed - indexed for MEDLINE]
-
References
- 1.↵
- McGuire WP,
- Hoskins WJ,
- Brade MF,
- et al
- 2.
- Piccart MJ,
- Bertelsen K,
- James K,
- et al
- 3.
- du Bois A,
- Luck HJ,
- Meier W,
- et al
- 4.↵
- Ozols RF,
- Bundy BN,
- Greer BE,
- et al
- 5.↵
- ten Bokkel Huinink W,
- Gore M,
- Carmichael J,
- et al
- 6.
- Creemers GJ,
- Bolis G,
- Gore M,
- et al
- 7.
- Hoskins P,
- Eisenhauer E,
- Beare M,
- et al
- 8.↵
- Bookman MA,
- Malstrom H,
- Bolis G,
- et al
- 9.↵
- Kudelka AP,
- Tresukosol D,
- Edwards CL,
- et al
- 10.↵
- Bolis G,
- Scarfone G,
- Villa A,
- Parazinni F,
- et al
- 11.↵
- Hoskins P,
- Eisenhauer E,
- Vergote I,
- et al
- 12.↵
- Aaronson NK,
- Ahmedzai S,
- Bergman B,
- et al
- 13.↵
- Cull A,
- Howat S,
- Greimel E,
- et al
- 14.↵
- Therasse P,
- Arbuck SG,
- Eisenhauer EA,
- et al
- 15.↵
- Vergote I,
- Rustin GJ,
- Eisenhauer EA,
- et al
- 16.↵
- Markman M,
- Federico M,
- Liu PY,
- Hannigan E,
- Alberts D
- 17.↵
- van Dalen A,
- Favier J,
- Burges A,
- et al
- 18.↵
- Chow SC
- Tu D
- 19.↵
- Bookman MA,
- Brady MF,
- McGuire WP,
- et al
- 20.↵
- Romanelli S,
- Perego P,
- Pratesi G,
- et al
- 21.↵
- Pfisterer J,
- Weber B,
- Reuss A,
- et al
- 22.
- De Placido,
- Scambia G,
- Di Vagno G,
- et al
- Scarfone G,
- Scambia F,
- Raspagliesi G,
- et al
- 1.↵
Gerelateerde artikelen
- Topotecan als eerste lijns in combinatie met platina chemokuren geeft geen enkele meerwaarde in effectiviteit en zelfs meer en ernstigere bijwerkingen blijkt uit fase 2 studie in meerdere ziekenhuizen.
- Chemo bij eierstokkanker: een overzicht van recente ontwikkelingen en belangrijke studie abstracten en artikelen.
Plaats een reactie ...
Reageer op "Topotecan geeft in fase III studie geen enkele meerwaarde, zelfs kortere tijd tot recidief, na operatie toegediend bij eierstokkankerpatiënten stadium III en IV tegenover carboplatin - paclitaxel."